Analysis Suggests Increased Overall Survival with Use of Higher Cumulative Dose of Velcade (bortezomib) in Patients with Previously Untreated Multipl

09-12-2013 Business Wire HealthComments (0)

PharmaceuticalTakeda NycomedVelcade

Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited (TSE:4502), today announced results from a retrospective, subgroup analysis of the Phase 3 VISTA study that showed a higher cumulative dose of VELCADE® (bortezomib) suggests improved overall survival (OS) in previously untreated patients with multiple myeloma (MM) (hazard ratio [HR] 0.53; p

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top